Novel anticancer drug discovery

Current Opinion in Chemical Biology

Volumn 3, Issue 4, 1999, Pages 500-509

  Buolamwini, John K ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIN; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; CELL ADHESION MOLECULE; CYCLIN DEPENDENT KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN MDM2; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; TELOMERASE; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; BIOLOGY; CANCER; CELL PROLIFERATION; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG TARGETING; HUMAN; METASTASIS; ONCOGENE NEU; PROTEIN MODIFICATION; REVIEW;

EID: 0033178247     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(99)80073-8     Document Type: Article

References (61)

1. Akinaga S: Molecular target therapy of cancer. D. Cancer genes and cancer regulating genes. Kagaku Ryo no Ryoiki 1998, 14:33-40. This provides a recent review of novel molecular targets for anticancer drug discovery and their involvement in various cancers.
2. Jones DA, Fitzpatrick FA: Genomics and the discovery of new drug targets. Curr Opin Chem Biol 1999, 3:71-76. This paper provides a good review on how genomics and proteomics are impacting the discovery and validation of novel molecular targets for drug discovery in general.
3. Ishioka C, Kato S, Kanamaru R: Current strategies on discovery of anticancer drugs in the United States of America. Saishin Igaku 1998, 53:1940-1945.
4. Gray NS, Wodika L, Thunnissen A-MWH, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, LeClerc S, Meijer L et al.: Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998, 281:533-538. A comprehensive and integrated study demonstrating the use of combinatorial chemistry to explore the effects of a diverse array of substituents on the purine ring in oloumucine, and high-throughput screening with 24 purified protein kinase systems. This led to the discovery of highly specific purine inhibitors of human Cdc2, a cyclin-dependent kinase. The cellular effects of the inhibitors were characterized in mammalian cells employing the genomics technique of high density oligonucleotide probe arrays.
5. Marais R, Light Y, Mason C, Paterson H, Olson MF, Marshall CJ: Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science 1998, 280:109-112. Elegant study using COS cells to show that protein kinase C (PKC) is an upstream regulator of Ras (as far as PKC activation of Raf-1 is concerned) and demonstrates the essential role of Ras in the activation of the ERK MAPK cascade by PKC.
6. waf1/cip1.
7. Khosavi-Far R, Campbell S, Rossman KL, Der CJ: Increasing complexity of Ras signal transduction: Involvement of Rho family proteins. Adv Cancer Res 1998, 72:57-107. This is an extensive review showing that Raf-1 is not the only downstream effector of Ras, and also that Rho family proteins are important in Ras transformation.
8. Tzahar E, Yarden Y: The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: From orphanhood to multiple stromal ligands. Biochim Biophys Acta 1998, 1377:M25-M37. This is a comprehensive review, putting HER-2/neu in the context of other type 1 growth factor receptor and ligand interactions.
9. Farah RA, Clinchy B, Herrera L, Vitetta ES: The development of monoclonal antibodies for the therapy of cancer. Crit Rev Eukaryot Gene Exp 1998, 8:321-356. This is a comprehensive, recent review giving a historical background and an account of the development of, and clinical applications of, monoclonal anti-bodies for the therapy of various cancers, unconjugated or conjugated with toxins, alone or in combination with other treatment modalities.
10. Kip1 and decreased activity of CDKs.
11. Klutchko SR, Hamby JM, Boschelli DH, Wu Z, Jraker AJ, Amar AM, Hartl BG, Shen C, Klohs WD, Steinkampf RW et al.: 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J Med Chem 1998, 41:3276-3292. This is an extensive study extending the structure/activity relationships of a new class of compounds identified through library screening with broad and selective potentencies against a host of major tyosine kinases both in vitro and in vivo.
12. Trump-Kallmeyer S, Rubin JR, Humblet C, Hamby JM, Showalter HDH: Development of a binding model of protein tyrosine kinase for substituted pyrido[2,3-d]pyrimidine inhibitors. J Med Chem 1998, 41:1752-1763. This is a study using structure/activity relationship information and molecular modeling to propose a binding model for pyrido[2,3-d]pyrimidine inhibitors at the ATP-binding site of tyrosine kinases.
13. Fong TAT, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Shreck R, Wang X, Risau W et al.: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999, 59:99-106. This is a study demonstrating the anti-angiogenic and broad in vivo antitumor activity of a selective VEGFR inhibitor.
14. Kolb AJ, Kaplita PV, Hayes DJ, Park YW, Pernell C, Major JS, Mathis G: Tyrosine kinase assays adapted to homogenous time-resolved fluorescence. Drug Discov Today 1998, 3:333-342.
15. Yao Z-J, King CR, Cao T, Kelly J, Milne GWA, Voigt JA, Burke TR Jr: Potent inhibitors of Grb2 SH2 domain binding by non-phosphate-containing ligands. J Med Chem 1999, 42:25-35. This is a well executed study reporting a new series of nonphosphate-containing phosphotyrosine mimetic Grb2 SH2 peptides that feature a Nα-oxalyl group which enhances binding potency as measured by surface plasmon resonance. The study also demonstrated the ability of these new compounds to block Grb2-HER-2/neu oncogene interaction in cells by an immunoprecipitation.
16. Boriack-Sjodin PA, Margait SM, Bar-Sagi D, Kuriyan J: The structural basis of the activation of Ras by Sos. Nature 1998, 394:337-343. This study provides the first three-dimensional structural information showing the mutual domains of interaction between the GTP-binding protein Ras and its major upstream regulator Sos.
17. Lee TR, Lawrence DS: Acquisition of high-affinity SH2-targeted ligands via a spatially focused library. J Med Chem 1999, 42:784-787. This is a study that utilized a parallel combinatorial library approach to discover ligands that can discriminate among different SH2 domains.
18. Lobell RB, Kohl NE: Pre-clinical development of farnesyltransferase inhibitors. Cancer Metastasis Rev 1998, 17:203-210. This is a review highlighting the preclinical development of Ras farnesyltransferase inhibitors as anticancer agents, with examples.
19. Mallams AK, Rossman RR, Doll RJ, Girijavallabhan VM, Ganguly AK, Petrin J, Wang L, Patton R, Bishop WR, Carr DM et al.: Inhibitors of farnesyl protein transferase. 4-amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-Bromo-8-chloro-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine. J Med Chem 1998, 41:877-893. This is an extensive study involving the synthesis and structure/activity relationship studies of a series of novel tricyclic farnesyltransferase (FTase) inhibitors, and the derivation of a FTase inhibitory pharmacophore for the series.
20. ..]) to substantially enhance oral bioavailability and pharmacokinetic profiles.
21. Long SB, Casey PJ, Beese LS: Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate. Biochemistry 1998, 37:9612-9618. This study reports the first X-ray crystallographic structure (at 3.4 Å resolution) of the complex between farnesyltransferase and its farnesyl diphosphate substrate.
22. Lebowitz PF, Prendergast GC: Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho. Oncogene 1998, 17:1439-1445. This is a recent review on the mechanisms of action of farnesyltranferase inhibitors, shedding some light on the unexpected results that have been obtained with these novel anticancer agents. Their effects on the Ras-related protein Rho is proposed to alter Rho-dependent cell adhesion, which may help to address some of the questions that still remain in the biological effects observed with farnesyltransferase inhibitors, and their lack of toxicity to normal cells.
23. Bernhard EJ, McKenna WG, Hamilton AD, Sebti SM, Qian Y, Wu JM, Muschel RJ: Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating Ras oncogenes. Cancer Res 1998, 58:1754-1761. This study shows the potential of combining Ras prenylation inhibition with radiation therapy to enhance cancer therapy.
24. Hunter T: Oncoprotein networks. Cell 1997, 88:573-582.
25. Monia BP: First- and second-generation antisense inhibitors targeted to human c-raf kinase: In vitro and in vivo studies. Anticancer Drug Des 1997, 12:327-339.
26. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995, 92:7686-7689.
27. Capronigro F, French RC, Kaye SB: Protein kinase C: A worthwhile target for anticancer drugs? Anticancer Drugs 1997, 8:26-33.
28. Schwartz GK: Protein kinase C inhibitors as inducers of apoptosis for cancer treatment. Exp Opin Invest Drugs 1996, 5:1601-1615.
29. Qiao L, Wang S, George C, Lewin LE, Blumberg PM, Kozikowski AP: Structure-based design of a new class of protein kinase C modulators. J Am Chem Soc 1998, 120:6629-6630. A study applying computer-aided drug design methods to discover novel γ-lactam ligands of PKC based on X-ray crystallographic structural information.
30. Latchman DS: Transcription-factor mutations in disease. N Engl J Med 1996, 334:28-33.
31. Coleman KG, Lyssikatos JP, Yang BV: Chemical inhibitors of cyclin-dependent kinases. Ann Rep Med Chem 1997, 32:171-179.
32. Pines J: Cyclin-dependent kinases: The age of crystals. Biochim Biophys Acta 1997, 1332:M39-M42.
33. Imoto M: Molecular target therapy of cancer: A. Cell cycle. Kagaku Ryo no Ryoiki 1998, 14:13-19.
34. Christain MC, Puda JM, Ho PTC, Arbuck SG, Murgo AJ, Sausville EA: Promising new agents under development by the division of cancer treatment, diagnosis, and centers of the National Cancer Institute. Sem Oncol 1997, 24:219-240.
35. Levine AJ: p53 the cellular gate keeper for growth and division. Cell 1997, 88:323-331.
36. Wang H-G, Reed JC: Mechanisms of Bcl-2 protein function. Histol Histopathol 1998, 13:521-530. This is an excellent, recent comprehensive review on the structure and function of the Bcl-2 protein family in terms of their being anti-apoptotic or proapoptotic, as well as the multiple targets and functions of Bcl-2.
37. Freedman DA, Wu L, Levine AJ: Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999, 55:96-107. This is an excellent recent review on the structure and function of MDM2 as a suppressor of p53 in an autoregulatory feedback loop, p53-independent oncogenic functions of MDM2, and the potential of targeting MDM2-p53 interactions or MDM2 for anticancer therapy.
38. Berghella AM, Pellegrini P, Contasta I, Del Beato T, Adorno D: Bcl-2 and drugs used in the treatment of cancer: Newer strategies of biotherapy which should not be underestimated. Cancer Biother Radiopharm 1998, 13:225-237. This is a review on Bcl-2 expression in cancer, its relationship to tumor resistance towards radiation and anticancer drugs, and the investigation of compounds that will enhance tumor drug response by indirectly regulating Bcl-2.
39. Oltersdorf T, Fritz LC: The Bcl-2 family: Targets for the regulation of apoptosis. Annu Rep Med Chem 1998, 33:253-262. This is a recent review of the Bcl-2 family of proteins as targets for the regulation of apoptosis.
40. Arf with MDM2 to abrogate MDM's suppression of p53.
41. Chen L, Agrawal S, Zhou W, Zhang R, Chen Z: Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci USA 1998, 95:195-200. This is an elegant study that clearly demonstrates the ability to enhance p53 function by downregulating MDM2 expression.
42. Ambrosini G, Adida C, Sirugo G, Altieri DC: Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998, 273:11177-11182. This is an interesting study that further characterizes Survivin as an anti-apoptotic protein, and indicates that this protein could be a selective anticancer target.
43. Folkman J: Endogenous inhibitors of angiogenesis. Harvey Lect Ser 1998, 92:65-82. This is a comprehensive review giving a historical background to angiogenesis research and the discovery of angiogenesis and anti-angiogenesis molecules, as well as the experimental development of anti-angiogenesis polypeptides as agents for cancer treatment that bypass drug resistance.
44. Nelson NJ: News item: Inhibitors of angiogenesis enter phase III testing. J Natl Cancer Inst 1998, 90:960-963. A summary of various angiogenesis inhibitors that are being evaluated in clinical trials for cancer therapy.
45. Powell D, Skotnicki J, Upeslacis J: Angiogenesis inhibitors. Annu Rep Med Chem 1997, 32:161-170.
46. Mordenti J, Thomsen K, Licko V, Chen H, Meng YG, Ferrara N: Efficacy and contration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol Pathol 1999, 27:14-21. This is a study that investigated efficacy of a monoclonal antibody against VEGF in mice and the appropriate dosing of this antibody to be used in human trials.
47. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard SR, Schlessinger J: Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997, 276:955-960.
48. Rabbani SA: Metalloproteases and urokinase in angiogenesis and tumor progression. In Vivo 1998, 12:135-142. This is a recent review discussing MMPs and urokinase in tumor progression, with an emphasis of the role of urokinase in prostrate and breast cancer.
49. Weidle UH, Konig B: Urokinase receptor antagonists: Novel agents for the treatment of cancer. Exp Opin Invest Drugs 1998, 7:391-404. This is a review of urokinase receptor activity in a variety of cancers and its antagonists as potential anticancer agents.
50. Edwards DR, Murphy G: Proteases - Invasion and more. Nature 1998, 394:527-528.
51. Kim J, Wu W, Kovalski K, Ossowski L: Requirement of specific proteases in cancer cell intravasation as revealed by a novel semi-quantitative PCR-based assay. Cell 1998, 94:335-362. An elegant study delineating the requirement of specific MMPs in cancer extravasation.
52. Summers JB, Davidsen SK: Matrix metalloproteinase inhibitors and cancer. Annu Rep Med Chem 1998, 33:131-140. A recent review of matrix metalloproteinase inhibitors as potential anticancer drugs.
53. Rothenberg ML, Nelson AR, Hande KR: New drugs on the horizon: Matrix metalloproteinase inhibitors. The Oncologist 1998, 3:271-274. This is a recent summary of the clinical evaluation status of major matrix metalloprotease inhibitors.
54. Shao Z-M, Wu J, Shen Z-Z, Barsky SH: Genistein inhibits both constitutive and EGF-stimulated invasion in ER-negative human breast carcinoma cell lines. Anticancer Res 1998, 18:1435-1440. This study demonstrates that the anti-invasion effects of genistein, a much investigated isoflavone anticancer agent, involves matrix metalloproteinases.
55. El-Hariry I, Pignatelli M: Adhesion molecules: Opportunities for modulation and a paradigm for novel therapeutic approaches in cancer. Exp Opin Invest Drugs 1997, 6:1465-1478.
56. Buckley CD, Pilling D, Henriquez NV, Parsonage G, Threlfall K, Scheel-Toellner D, Simmons DL, Acbar AN, Lord JM, Salmon M: RGD peptides induce apoptosis by direct caspase-3 activation. Nature 1998, 397:534-539. This is an interesting study showing an integrin-independent induction of apoptosis by RGD peptides.
57. Nicolaou KC, Trujillo JI, Jandeleit B, Chibale K, Rosenfeld M, Diefenbach B, Cheresh DA, Goodman SL: Design synthesis and biological evaluation of nonpeptide integrin antagonists. Bioorg Med Chem 1998, 6:1185-1208. This paper includes a description of the design synthesis and biological evaluation of new, potent, small-molecule inhibitors of integrins, which also show antiangiogenic activity.
58. Hiyama K, Hiyama E: Telomerase as a novel target for anticancer therapy. Mol Med 1998, 35:1374-1382. This is a concise, recent review of telomerase, its occurrence in cancers and approaches targeting telomerase for cancer therapy.
59. Perry PJ, Gowan SM, Reszka AP, Polucci P, Jenkins TC, Kelland LR, Niedle S: 1,4- and 2,6-Disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase. J Med Chem 1998, 41:3253-3260. This is a recent study describing the synthesis and biological evaluation of new anthracenedione analogs as potent telomerase inhibitors and anticancer agents.
60. Bare LA, Trinh L, Wu S, Devlin JJ: Identification of a series of potent telomerase inhibitors using a time-resolved fluorescence-based assay. Drug Dev Res 1998, 43:109-116. This is a study using a new telomerase assay for the discovery of novel inhibitors.
61. Burger AM, Bibby MC, Double JA: Telomerase activity in normal and malignant mammalian tissues: Feasibility of telomerase as a target for cancer chemotherapy. Br J Cancer 1997, 75:516-522.